Precigen, Inc. (NASDAQ:PGEN) Stock Position Increased by Barclays PLC

Barclays PLC boosted its position in shares of Precigen, Inc. (NASDAQ:PGEN) by 190.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 189,353 shares of the biotechnology company’s stock after buying an additional 124,141 shares during the quarter. Barclays PLC owned 0.06% of Precigen worth $179,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of PGEN. SG Americas Securities LLC raised its holdings in shares of Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 13,823 shares during the period. Exchange Traded Concepts LLC grew its position in Precigen by 10.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 15,525 shares in the last quarter. Stifel Financial Corp lifted its holdings in shares of Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Precigen by 40.7% in the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after buying an additional 16,486 shares during the period. Finally, AQR Capital Management LLC lifted its stake in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on PGEN. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Precigen in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.33.

Precigen Stock Down 4.2 %

Shares of NASDAQ:PGEN opened at $1.13 on Thursday. The company has a market cap of $330.94 million, a price-to-earnings ratio of -2.05 and a beta of 1.65. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $1.93. The business has a 50 day moving average price of $0.92 and a 200 day moving average price of $1.06.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.